title: Recent Advances in the Pharmacological Management of Atrial Fibrillation.
abstract: Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia that leads to hospitalizations for complications and adverse events each year. Despite significant improvement in our therapeutic approaches in the past decade, management of AF remains a difficult task. Novel therapies have failed to terminate AF and prevent its recurrence, and patients with AF continue to have thromboembolic complications. With the increasingly aging population and associated conditions, the prevalence of AF is expected to progressively increase, becoming a public health problem. Most patients with AF have multiple comorbidities and are of advanced age, making long-term anticoagulation challenging. This article provides an overview of the current pharmacological therapies for the management of AF, with particular emphasis on the emerging agents.
authors.affiliation: 1Department of Internal Medicine, Mayo Clinic, Rochester, MN; 2Division of Cardiology, Sanger Heart and Vascular Institute, Charlotte, NC; 3Department of Pharmacy Services and 4Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
authors.forename: Janelle Y
authors.initials: JY
authors.lastname: Gooden
authors.forename: Brian D
authors.initials: BD
authors.lastname: Powell
authors.forename: Clement O
authors.initials: CO
authors.lastname: Akogyeram
authors.forename: Rowlens M
authors.initials: RM
authors.lastname: Melduni
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000145:classification / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D000991:Antithrombins / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D000991:Antithrombins; D010975:Platelet Aggregation Inhibitors